#NewAseBioMember | "AseBio is a key reference entity in the Spanish and European biotechnology sector"

AseBio. What does your company's work bring to the table and what is its strength?

Estephan Córdova. BeCytes Biotechnologies aims to manage, coordinate, and provide scientific and technical services related to the procurement, processing, preservation and distribution of tissues, cells and related products for research, being the hepatic area our main area of expertise.

Our strength lies in our ability to develop and refine these in-vitro cellular models, which allow the most accurate and detailed analysis of the effects of drugs.
By providing these more accurate validation tools, we help ensure the safety and efficacy of drug treatments, which ultimately has a significant impact on people's health and well-being.

AseBio. What is AseBio for you?

Estephan Córdova. AseBio is a key reference entity in the Spanish and European biotechnology sector. It represents an invaluable platform that will allow us to consolidate our organization through access to knowledge, internationalization, and institutional support.

AseBio. When did you first hear about AseBio?

Estephan Córdova. The first time we heard about ASEBIO was during one of the several international trade missions in which Becytes Biotechnologies has participated during the last years. During these events, ASEBIO was an important strategic partner. 

Therefore, we were able to perceive the important role played by ASEBIO in promoting and boosting the Spanish biotechnology industry at an international level. 

Likewise, BeCytes Biotechnologies has always valued the importance of the biotechnological activity at national level and, since we have been aware of its existence, we have considered ASEBIO as a key player and reference in this field.

AseBio. What do you expect from being part of an association like AseBio?

Estephan Córdova. Being part of an association such as ASEBIO, our expectations are focused on contributing significantly to the consolidation and continued development of the biotechnology sector. Specifically, we hope to contribute our knowledge in the generation of in-vitro cellular models that favour the development of advanced therapies and drug testing.

Our participation in AseBio gives us the opportunity to collaborate with other members, share best practices, promote research and innovation, and establish synergies that drive progress in these specialized areas. We hope not only to benefit from the collective experience of the association, but also to contribute our expertise to strengthen and enrich knowledge within the sector.

In short, we hope that our participation in ASEBIO will allow us to be an active and constructive voice that contributes to the growth and excellence of the biotechnology sector.

AseBio. What is the biggest challenge facing the biotech sector (or your company)?

Estephan Córdova.The biggest challenge we face in the biotechnology sector, including our company, is the development of more advanced in-vitro predictive tools that can more accurately replicate the human microenvironment in-vivo. These advances are crucial as they will significantly reduce the need for animal testing, while improving the ability to predict the efficacy and safety of drugs and the development of advanced therapies.

Secondly, another important challenge that we would like to contribute to achieving is the inclusion and recognition of the Spanish biotechnology sector at the international level. Achieving this recognition will open new opportunities for collaboration, investment and development, which will contribute to the realization of projects with greater visibility and the consolidation of leading players at the national level.